ABSTRACT
Andrew V. Schally, Magdolna Kovacs, Katalin Toth, and Ana Maria Comaru-Schally Tulane University School of Medicine and Veterans Affairs Medical Center, New Orleans, Louisiana
I. INTRODUCTION
There is an even greater clinical need for antagonistic analogs of GHRH (9-11). The GHRH antagonists could be tried in conditions such as acromegaly, diabetic retinopathy, or diabetic nephropathy (glomerulosclerosis). However, the main applications of GHRH antagonists would be in the field of cancer (10; see Sec. VI on potential clinical uses).
